Key result
Dabigatran use in the peri-procedural period for radiofrequency ablation of atrial fibrillation showed no significant difference in major bleeding compared to warfarin and heparin bridging (3.0% vs 3.2%, p=0.93), but significantly shortened hospital stay.
Why the study?
Does peri-procedural dabigatran improve safety, efficacy, and duration of hospital stay compared to warfarin and heparin bridging in patients undergoing radiofrequency catheter ablation for atrial fibrillation?
Cohort (n=227)
No
Does peri-procedural dabigatran improve safety, efficacy, and duration of hospital stay compared to warfarin and heparin bridging in patients undergoing radiofrequency catheter ablation for atrial fibrillation?
Absolute Event Rate: 3% vs 3.2%
p-value: p=0.93
Peri-procedural dabigatran for RFCA of AF is as safe and effective as warfarin with heparin bridging, and significantly reduces the duration of hospital stay.
No takes yet. Share an insight, caveat, or question.
May shorten hospital stay without excess bleeding in AF ablation; leaves open need for randomized confirmation.
Imamura et al. (2013) conducted a cohort in Atrial fibrillation (n=227). Dabigatran vs. Warfarin and heparin bridging was evaluated on Major bleeding complications (p=0.93). Dabigatran use in the peri-procedural period for radiofrequency ablation of atrial fibrillation showed no significant difference in major bleeding compared to warfarin and heparin bridging (3.0% vs 3.2%, p=0.93), but significantly shortened hospital stay.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: